Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2017 (2017), Article ID 4848076, 10 pages
https://doi.org/10.1155/2017/4848076
Review Article

Compound Danshen Dripping Pill for Treating Nonproliferative Diabetic Retinopathy: A Meta-Analysis of 13 Randomized Controlled Trials

1Department of Endocrinology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beixiange 5, Xicheng District, Beijing 100053, China
2China Academy of Chinese Medical Sciences, Beixiange 5, Xicheng District, Beijing 100700, China

Correspondence should be addressed to Fengmei Lian; moc.uhos@565mfl

Received 4 December 2016; Revised 12 February 2017; Accepted 23 April 2017; Published 24 August 2017

Academic Editor: Mona Abdel-Tawab

Copyright © 2017 Wenjing Huang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Objective. We assess the clinical effect of compound Danshen dripping pill (CDDP) for treating diabetic retinopathy (DR). Methods. Electronic databases were searched from January 2001 to October 2016 to locate randomized controlled trials (RCTs). Efficacy was measured as main outcome and microaneurysms, hemorrhage, exudate, vision, and fundus fluorescein angiography (FFA) were measured as second outcomes. Methodological quality for each study was evaluated, RevMan 5 software was used to assess treatment effects, and GRADE was used to rate quality of evidence. Results. We located 13 RCTs and methodological quality was evaluated as high risk. Statistics indicated CDDP for treating DR was better than controls and DR risk was reduced 64% with CDDP (RR: 0.36, ); retinal microaneurysms (MD = −4.32NO, ); retinal hemorrhages (MD = −0.70PD, ); exudate improvements (MD = −0.09PD, ); visual changes (MD = −0.12 letter, ); FFA (RR: 0.40, ). About GRADE, quality of evidence was “low.” Conclusion. CDDP may be safe and efficacious for treating or delaying DR and may improve vision or delay vision loss.